FDA
-
-
-
-
-
-
-
Liquidia Technologies (LQDA) Announces Preliminary Full-Year 2025 YUTREPIA Net Sales and Corporate Update
-
-
-
-
-
-
-
Raymond James on Liquidia Technologies (LQDA): 'we maintain our positive outlook for the simultaneous Yutrepia launches in PAH and PH-ILD'
-
-
-
-
-
-
-
Raymond James Reiterates Strong Buy Rating on Liquidia Technologies (LQDA)
-
-
-
-
-
-
-
Liquidia Corporation Reports First Quarter 2025 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Liquidia Corporation Strengthens Financial Position by Amending HealthCare Royalty Agreement to Incrementally Add Up to $100 Million
-
-
-
-
-
-
-
Liquidia Technologies (LQDA) Reports Court Found United Therapeutics’ Interference with Launch of Generic Treprostinil Injection Caused Losses of over $137M
-
-
-
-
-
-
-
Liquidia Technologies (LQDA) PT Lowered to $23 at BofA Securities
-
330,175 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

